Paraneoplastic spastic tetraparesis in a glucagonoma syndrome. Successful therapy by octreotide, dacarbazine, and interferon-α;Paraneoplastische spastische Tetraparese bei Glukagonomsyndrom. Erfolgreiche Therapie mit Octreotide, Dacarbazin und Interferon-α

Zeitschrift fur Gastroenterologie

Volumn 34, Issue 7, 1996, Pages 438-445

  Strohm, W D ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Medizinische Klinik II   (Germany)

Author keywords

dacarbazine; glucagonome syndrome; interferon ; octreotide

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; GLUCAGON; INSULIN; OCTREOTIDE; POVIDONE IODINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GLUCAGONOMA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER TUMOR; MALE; PANCREAS TUMOR; PARANEOPLASTIC SYNDROME; QUADRIPLEGIA; SKIN DISEASE; SPLENECTOMY; TOPICAL DRUG ADMINISTRATION;

ADULT; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DIAGNOSTIC IMAGING; GLUCAGON; GLUCAGONOMA; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; OCTREOTIDE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PARANEOPLASTIC SYNDROMES; QUADRIPLEGIA;

EID: 0029942244     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Arnaud A, Petissof F, Lorette G et al. Le syndrome du glucagonome trois nouveaux cas. Rev Med Interne 1992; 13. 103-8
2. Chang CH, Sheu HM, Gheng GS, Yu HS Necrolytic migratory erythema as the fist manifestation of giucagonoma. Taiwan I Hsueh Hui Tsa Chih 1991; 90: 1240-5
3. Edney JA, Hofmann S, Thompson JS, Kessinger A Glucagonoma syndrome is an underdiagnosed clinical entity Am J Surg 1990; 160: 625-9
4. Fujita J, Seino Y, Ishida H et al. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome. Cancer 1986, 57 860-5k
5. Hashizume T, Kiryu H, Noda K, Kano T, Nakano R. Glucagonoma syndrome J Am Acad Dermatol 1988; 19: 377-83
6. Hunt SJ, Narus VT, Abell E. Necrolytic migratory erythema, dyskeratotic dermatitis, a clue to early diagnosis. J Am Acad Dermatol 1991, 24: 473-7
7. Kasper CS Necrolytic migratory erythema unresolved problems in diagnosis and pathogenesis A case report and literature review Cutis 1992; 49: 120-2, 125-8
8. Long CC, Laidler P, Holt PJ. Suprabasal acantholysis - an unusual feature of necrolytic migratory erythema. Clin Exp Dermatol 1993, 18: 464-7
9. Shepherd ME, Raimer SS, Tyring SK, Smith EB. Treatment of necrolytic migratory erythema in glucagonoma syndrome. J Am Acad Dermatol 1991; 25: 925-8
10. Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Derm Syph 1942, 54: 1069-75
11. Bloom SR, Polak JM. Glucagonoma syndrome. Am J Med 1987; 82: 25-36
12. Hercot O, Legmann P, Humbert M et al. Diagnostic du glucagonome Interêt du scanner, de l'échographie et de l'arteriographie. A propos de deux observations et revue de la literature. J Radiol 1989; 70: 309-16
13. Lee KO, Chan HL, Lee HL. The glucagonoma syndrome in a Chinese man. Ann Acad Med 1985; 14: 312-6
14. Müller MK, Niederle N. Gastrointestinale hormonaktive Tumoren. Teil I: Pathophysiologie und Klinik. Teil II: Systemische Therapie. Med Klinik 1991; 85: 598-601 und 663-71
15. Parker CM, Hanke CW, Madura JA, Liss EC. Glucagonoma syndrome: case report and literature review. J Dermatol Surg Oncol 1984; 10: 884-9
16. Penchet A, Olivier A, Passa P, Orsoni JL, Charleux H. Le syndrome de glucagonome. Revue de la literature. A propos d'un cas. J Chir 1986, 123: 1157-463
17. Tajima Y. Glucagonoma. Nippon Geka Gakkai Zasshi 1984; 85: 1039-43
18. Vandersteen PR, Scheithauer BW. Glucagonoma syndrome. A clinicopathologic, immunocytochemical, and ultrastructural study. J Am Acad Dermatol 1985; 12: 1032-9
19. Haneke E. Imitation einer Glukagonom-Dermatitis durch erworbenen Zinkmangel. Histologie und Elektronenmikroskopie. Z Hautkr 1984; 59: 902-8
20. Kasper CS, McMurry KK. Necrolytic migratory erythema without glucagonoma versus canine superficial necrolytic dermatitis: is hepatic impairment a clue to pathogenesis? J Am Acad Dermatol 1991; 25: 534-41
21. Masri-Fridling GD, Turner MLC. Necrolytic migratory erythema without glucagonoma. J Am Acad Dermatol 1992; 27: 486
22. Doyle JA, Schroeter AL, Rogers RS. Hyperglucagonaemia and necrolytic migratory erythema in cirrhosis - possible pseudoglucagonoma-syndrome. Br J Dermatol 1979, 100: 581-7
23. Marinkowick MP, Botella R, Datloff J, Sangueza OP. Necrolytic migratory erythema without glucagonoma in patients with liver disease. J Am Acad Dermatol 1995; 32: 604
24. Ossowki B, Baum C. Das Pseudoglukagonom-Syndrom. Hautarzt 1995; 38: 173-6
25. Tanner M, Brasch J, Christophers E. Erythema necrolyticans migrans ohne Glukagonom. Hautarzt 1994; 45: 480-3
26. Herzberg JJ Paraneoplastische Syndrome in der Dermatologie Internist 1990; 31. 505-12
27. Sprogoe-Jakobsen U, Karkov JN. Benign pancreatic glucagonoma and recurrent pulmonary embolism with fatal course in a 36-year-old man. Ugeskr Laeger 1991; 153: 3015-6
28. Stöckmann F, Creutzfeldt W. Behandlung gastrointestinaler neuroendokriner Tumoren mit dem Somatostatin-Analog Octreotide (Sandostatin®). Z Gastroenterologie 1988; 26: 665-75
29. Klein S, Jahoor F, Baba H et al. In vivo assessment of the metabolic alterations in glucagonoma syndrome. Metabolism 1992; 41: 1171-5
30. Almdal TP, Heindorff H, Bardram L, Vilstrup H. Increased amino acid clearance and urea synthesis in a patient with glucagonoma Gut 1990; 31: 946-8
31. Holmes A, Kilpatrick C, Proietto J, Green MD. Reversal of a neurologic paraneoplastic syndrome with octreotide (Sandostatin) in a patient with glucagonoma. Am Int Med 1991; 91: 434-6
32. Lambrecht ER, van der Loos TL, van der Eerden AH. Retrobulbar neuritis as the first sign of the glucagonoma syndrome. Int Ophthalmol 1987. 11: 13-5
33. Achten G, Ledoux-Corbusier M, Goens J. Autonomie nosologique et pathogénie des syndromes paranéoplasiques cutanes. Ann Med Interne 1984, 135. 646-53
34. Arao T, Ohishi M, Yamada M, Nakamura T. Cutaneous-internal malignancy syndrome associated with specific skin lesions. Gan To Kagaku Ryoho 1988. 15: 1581-7
35. Chong LY, Lai CF, Woo CH et al. Necrolytic migratory erythema in glucagonoma syndrome. J Dermatol 1992; 19: 369-74
36. Engelmann L, Bonmann H, Kunze J, Haneke E. Erythema necrolyticum migrans - Glukagonom-Syndrom -. Akt Dermatol 1991; 17: 11-7
37. Galle K, Schweiß D. Das Glukagonom-Syndrom - eine wenig bekannte kutane Paraneoplasie. Ein kasuistischer Bericht. Hautarzt 1984; 35. 204-9
38. Kheir SM, Omura EF, Grizzle WE, Herrera GA, Lee I. Histologic variation in the skin lesions of the glucagonoma syndrome. Am J Surg Pathol 1986; 10: 445-53
39. Rappersberger K, Wolff-Schreiner E, Konrad K, Wolff K. Das Glukagonom-Syndrom. Hautarzt 1987; 38: 589-98
40. Wilkinson DS. L'érythème migrateur nécrolytique: syndrome du glucagonome. Aspects cliniques et histologiques. Ann Med Interne 1984; 135: 654-7
41. Grama D, Eriksson B, Martensson H et al. Clinical characteristics, treatment and survival in patiens with pancreatic tumors causing hormonal syndromes. World J Surg 1992; 16: 632-9
42. Reyes-Govea J, Holm A, Aldrete JS. Response of glucagonomas to surgical excision and chemotherapy. Report of two cases and review of the literature. Am Surg 1989; 55: 523-7
43. Howard TJ, Stabile BE, Zinner MI et al. Anatomic distribution of pancreatic endocrine tumors. Am J Surg 1990; 159: 258-64
44. Berney C, Clavien PA, Rohner A. Tumeurs endocrines du pancreas. Le point sur la question. Schweiz med Wschr 1993; 123 2123-37
45. Grant CS. Surgical management of malignant islet cell tumors. World J Surg 1993; 17: 498-503
46. Isaji S, Kato K, Tanigawa K. Diagnosis and surgical treatment for endocrine tumors of the pancreas. Rinsho Byori 1994; 42: 150-9
47. Modlin IM, Lewis JI, Ahlman H, Bilchik AJ, Kumar RR. Management of unresectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet 1993; 176: 507-18
48. Rikitake Y, Morita S, Kuroda S et al. A case report of glucagonoma recurred to the lymph nodes seven years after resection of the primary tumor. Nippon-Shokakibyo-Gakkai-Zasshi, 1994, 91: 227-31
49. Rosenbaum A, Flourie B, Chagnon S, Blery M, Modigliani R. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma. report of one case and review of the literature. Digestion 1989; 42 116-20
50. Altimari AF, Bhoopalam N, O'Dorsio T et al. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery 1986, 100: 989-96
51. Anderson JV, Bloom SR. Neuroendocrine tumours of the gut, long-term therapy with the somatostatin analogue SMS 201-995. Scand J Gastroenterol Suppl 1986; 119. 115-28
52. Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Owen OE. Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995 N Engl J Med 1986; 314: 1686-9
53. Kaloustian E, Guillauseau PJ, Chayvialle JA et al. Tumeur mixte du pancreas endocrine (vipome, glucagonome). Traitement par la somatostatine puis par un de ses analogues d'action prolongée Presse Med 1987; 16: 2217-20
54. Kvols LK, Buck M, Moertel CG et al. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 1987; 107: 162-8
55. Souquet JC, Sassolas G, Forichon J et al Clinical and hormonal effects of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 1987. 59: 1654-60
56. Williams G, Anderson JV, Williams SJ Bloom SR. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion Acta Endocrinol Suppl 1987; 286. 26-36
57. Arnold R, Neuhaus C, Trautmann ME Therapie endokriner gastroenteropankreatischer Tumoren mit dem Somatostatin-Analogon Octreotid Dtsch med Wschr 1992; 117: 1067-71
58. Ben Yosef R, Glaser B, Catane R. Somatostatin analogue in the treatment of neuroendocrine gut tumors. Harefuah 1990; 119: 15-8
59. Blanchin M, James-Deidier A, Chaumet-Riffaud PD, Chayvialle JA. Utilisation de l'octreotide dans les tumeurs endocrines digestives Etude francaise multicentrique. Presse Med 1992; 21. 697-702
60. Elsborg L, Glenthoj A. Effect of somatostatin in necrolytic migratory erythema of glucagonoma Acta Med Scand 1985; 218. 245-9
61. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci 1989; 34 (3 suppl.): 28S-39S
62. Schmid R, Allescher HD, Schepp W et al. Effect of somatostatin on skin lesions and concentrations of plasma amino acids in a patient with glucagonoma-syndrome. Hepatogastroenterology 1988; 35: 34-7
63. Woltering EA, Mozell EJ, O'Dorisio TM, Fletcher WS, Howe B. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors. Surg Gynecol Obstet 1988; 167: 453-62
64. Ahlman H, Ahlund L, Dahlstrom A, Grimelius L, Theodorsson E. Somatostatin analogue and tissue cultures in the study of a human malignant glucogonoma. J Surg Oncol 1990; 44: 191-9
65. Santangelo WC, Unger RH, Orci L et al. Somatostatin analog-induced remission of necrotytic migratory erythema without changes in plasma glucagon concentration. Pancreas 1986; 1: 464-9
66. Kubota A, Yamada Y, Kagimoto S et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994; 93: 1321-5
67. Bencini PL, Vigo GP, Caputo R. Necrolytic migratory erythema without glucagonoma in a heroin dependent patient. Dermatology 1994; 189: 72-4
68. Blackford S, Wright S, Roberts DL Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids Br J Dermatol 1991: 125: 460-2
69. Burton JL. Zinc and essential fatty acids therapy for necrolytic migratory erythema. Arch Dermatol 1993, 129. 246-8
70. Grossman LD, Shumak SL, George SR, Singer W, Zinmann B The effects of SMS 201-995 (Sandostatin) on metabolic profiles in insulin dependent diabetes mellitus J Clin Endocr Mebab 1989; 68: 63-7
71. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumors: effect of Sandostatin® on tumor growth (German Sandostatin® study group). Metabol Clin Exper 1992; 41. suppl. 2: 116-8
72. Bani D, Bani-Sacchi T, Biliotti G. A malignant tumor of the pancreas producing glucagonoma syndrome: immunocytochemistry and ultrastructure of liver metastases and comparison with the primary tumor Pancreas 1989; 4. 492-5
73. Yagihashi S, Yagihashi M, Nagai K. Cystic pancreatic glucagonoma in contact with insulinoma found in a hypoglycemic patient. Pathol Res Pract 1992; 188. 751-6
74. Ho PW, Moore GW, Hoge AF. Glucagonoma occurring as a large cystic abdominal mass. South Med J 1984; 77: 666
75. Hallengren B, Dymling JF, Manhem P, Tennvall L, Tibblin S. Unsuccessful DTIC treatment of a patient with glucagonoma syndrome. Acta Med Scand 1983; 213: 317-8
76. Jeanmougin M, Civatte J, Bonvalet D et al. Glucagonome métastatique. Remission complète par la dacarbazine. (Recul de cinq ans). Ann Dermatol Venereol 1988; 115: 717-9
77. Kurose T, Seino Y, Ishida H et al. Successful treatment of metastatic glucagonoma with dacarbazine. Lancet 1984; 1: 621-2
78. van der Loos TL, Lambrecht ER, Lambers JC. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. J Am Acad Dermatol 1987; 16: 468-72
79. Jones DV Jr, Samaan NA, Sellin RV, Ajani JA. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon. Am J Med 1992; 93: 348-9
80. Sheehan-Dare RA, Simmons AV, Cotterill JA, Janke PG. Hepatic tumors with hyperglucagonemia. Response of treatment with human lymphoblastoid interferon. Cancer 1988; 62 912-4